Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Affimed N.V. - Common Stock (NQ:AFMD)

0.7339 +0.0489 (+7.14%)
Streaming Delayed Price Updated: 2:40 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 51,698
Open 0.6950
Bid (Size) 0.7159 (5)
Ask (Size) 0.7339 (8)
Prev. Close 0.6850
Today's Range 0.6950 - 0.7339
52wk Range 0.5200 - 8.950
Shares Outstanding 15,227,463
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting
From Affimed N.V.
Via GlobeNewswire

Performance

YTD
-45.6%
-45.6%
1 Month
+18.0%
+18.0%
3 Month
-29.4%
-29.4%
6 Month
-80.8%
-80.8%
1 Year
-86.0%
-86.0%

More News

Read More
Affimed Receives Nasdaq Deficiency Notice Over Low Share Price: Retail’s In Wait-And-Wait Mode
Via Stocktwits
Topics World Trade
Exposures Tariff
A Look Ahead: Affimed's Earnings Forecast
Via Benzinga
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
From Affimed N.V.
Via GlobeNewswire
Affimed to Present at the Leerink Partners Global Healthcare Conference 2025
From Affimed N.V.
Via GlobeNewswire
Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)
From Affimed N.V.
Via GlobeNewswire
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
From Affimed N.V.
Via GlobeNewswire
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
From Affimed N.V.
Via GlobeNewswire
Affimed Reports Third Quarter 2024 Financial Results & Business Update
From Affimed N.V.
Via GlobeNewswire
Earnings Scheduled For November 14, 2024
Via Benzinga
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
From Affimed N.V.
Via GlobeNewswire
Affimed to Present at the Cantor Global Healthcare Conference 2024
From Affimed N.V.
Via GlobeNewswire
Affimed Reports Second Quarter 2024 Financial Results & Business Update
From Affimed N.V.
Via GlobeNewswire
Affimed Appoints Shawn M. Leland as Chief Executive Officer
From Affimed N.V.
Via GlobeNewswire
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
From Affimed N.V.
Via GlobeNewswire
AFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Affimed Reports First Quarter 2024 Financial Results & Business Update
From Affimed N.V.
Via GlobeNewswire
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
From Affimed N.V.
Via GlobeNewswire
Why Is German Biotech Affimed Stock Soaring On Monday?
Via Benzinga
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga

Frequently Asked Questions

Is Affimed N.V. - Common Stock publicly traded?
Yes, Affimed N.V. - Common Stock is publicly traded.
What exchange does Affimed N.V. - Common Stock trade on?
Affimed N.V. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Affimed N.V. - Common Stock?
The ticker symbol for Affimed N.V. - Common Stock is AFMD on the Nasdaq Stock Market
What is the current price of Affimed N.V. - Common Stock?
The current price of Affimed N.V. - Common Stock is 0.7339
When was Affimed N.V. - Common Stock last traded?
The last trade of Affimed N.V. - Common Stock was at 05/12/25 02:40 PM ET
What is the market capitalization of Affimed N.V. - Common Stock?
The market capitalization of Affimed N.V. - Common Stock is 11.18M
How many shares of Affimed N.V. - Common Stock are outstanding?
Affimed N.V. - Common Stock has 11M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.